Shedir Pharma Group S.p.A. (BIT:SHE) commences share repurchases on July 6, 2022, under the program mandated by the shareholders in the Annual General Meeting held on April 29, 2022. As per the mandate, the company is authorized to repurchase it's own shares such that it's not exceed 10% of the number of shares outstanding from time to time. The maximum repurchase price must not be more than 15% lower or higher than the official stock exchange price of the shares recorded by Borsa Italiana SpA (“Borsa Italiana”) in the session preceding each individual transaction – except in cases where the shares are subject to exchange, transfer, assignment or other non-monetary disposal deeds. The purpose of the repurchase program is to implement stock incentive plans, use as investment object for an efficient use of the liquidity generated by the characteristic activity of the company. The repurchased shares will be used to acquire a portfolio of treasury shares that can be used in the context of extraordinary finance transactions and/or other uses deemed of financial, managerial and strategic interest for the company. The repurchase authorization is valid for 18 months. As of April 14, 2022, the company had 11,430,000 shares in issue and no shares in treasury.

On June 17, 2022, the company announced a share repurchase program. Under the program, the company will repurchase it's own shares. The repurchase program is valid for 18 months from the date of the resolution.